ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Trial Profile

ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Galeterone (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARMOR2
  • Sponsors Novus Therapeutics; Tokai Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 26 Jul 2016 According to a Tokai Pharmaceuticals media release, the company plans to allow all patients currently enrolled in the ARMOR2 to continue on therapy following consultation with their physicians and study investigators and intends to evaluate its ongoing ARMOR2 expansion phase following the recommendation made by the independent Data Monitoring Committee (DMC) to discontinue ARMOR3-SV study (Profile 700252262).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top